Developing next generation electrochemical devices
using graphene and other speciality transistors to create
a ‘lab-on-a-chip’.
A key factor in biochip development is the convergence of nanodevice fabrication and biochemistry. Biochips take advantage of device miniaturisation to enable efficient diagnostics. They combine several laboratory functions in regions on the same chip to process, detect and analyse biological specimens. To pave the way for on-chip multiplex diagnostics, Archer is developing a graphene-based biochip.
The Archer Biochip team is developing a miniature ‘lab-on-a-chip’ device for medical diagnostics. The devices are being designed to provide accurate and rapid measurement and detection of biomarkers with the ultimate aim of at-home use. Capability is being developed to allow it to test for multiple diseases in one sample on a single device.
A core part of the Biochip is its biosensor, known as the graphene field effect transistor (gFET). Archer has already created several generations of the gFET with multiple foundry partners to further derisk the technology.
By having a miniaturised ‘lab-on-a-chip’, Archer aims to provide better access to healthcare across the globe and improved patient outcomes through enhanced diagnostics.
Newsletter
Commentary
Designed by Aaron Knight.
